ES2440938T3 - Formas anhidrato de un derivado de piridina - Google Patents
Formas anhidrato de un derivado de piridina Download PDFInfo
- Publication number
- ES2440938T3 ES2440938T3 ES10747619.4T ES10747619T ES2440938T3 ES 2440938 T3 ES2440938 T3 ES 2440938T3 ES 10747619 T ES10747619 T ES 10747619T ES 2440938 T3 ES2440938 T3 ES 2440938T3
- Authority
- ES
- Spain
- Prior art keywords
- compound
- formula
- crystalline anhydrate
- disorders
- disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000003222 pyridines Chemical class 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 107
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 45
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 39
- 208000035475 disorder Diseases 0.000 claims description 34
- 239000007787 solid Substances 0.000 claims description 33
- 208000028017 Psychotic disease Diseases 0.000 claims description 26
- 239000000523 sample Substances 0.000 claims description 26
- 239000000126 substance Substances 0.000 claims description 25
- 208000019901 Anxiety disease Diseases 0.000 claims description 24
- 208000019116 sleep disease Diseases 0.000 claims description 23
- 239000008194 pharmaceutical composition Substances 0.000 claims description 18
- 208000019022 Mood disease Diseases 0.000 claims description 16
- 238000011282 treatment Methods 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 15
- 238000001228 spectrum Methods 0.000 claims description 15
- 238000011321 prophylaxis Methods 0.000 claims description 13
- 230000036506 anxiety Effects 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 11
- 208000011117 substance-related disease Diseases 0.000 claims description 11
- 238000005481 NMR spectroscopy Methods 0.000 claims description 8
- 239000003085 diluting agent Substances 0.000 claims description 5
- 238000001208 nuclear magnetic resonance pulse sequence Methods 0.000 claims description 5
- 238000002560 therapeutic procedure Methods 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 4
- 239000000243 solution Substances 0.000 description 73
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 47
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 39
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 38
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 38
- 239000010410 layer Substances 0.000 description 35
- 238000006243 chemical reaction Methods 0.000 description 33
- 238000000034 method Methods 0.000 description 33
- 239000000203 mixture Substances 0.000 description 30
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 26
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 24
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
- -1 4-fluoro-2-methylphenyl Chemical group 0.000 description 16
- 235000019439 ethyl acetate Nutrition 0.000 description 16
- 239000002249 anxiolytic agent Substances 0.000 description 15
- 230000000949 anxiolytic effect Effects 0.000 description 15
- 230000000147 hypnotic effect Effects 0.000 description 15
- 239000000932 sedative agent Substances 0.000 description 15
- 230000001624 sedative effect Effects 0.000 description 14
- 238000004128 high performance liquid chromatography Methods 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 12
- 208000005374 Poisoning Diseases 0.000 description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 12
- 231100000572 poisoning Toxicity 0.000 description 12
- 230000000607 poisoning effect Effects 0.000 description 12
- 206010012218 Delirium Diseases 0.000 description 11
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 11
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 11
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 10
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 10
- 229950010883 phencyclidine Drugs 0.000 description 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 10
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 229940025084 amphetamine Drugs 0.000 description 9
- 239000010949 copper Substances 0.000 description 9
- 238000000113 differential scanning calorimetry Methods 0.000 description 9
- 230000002085 persistent effect Effects 0.000 description 9
- 235000021395 porridge Nutrition 0.000 description 9
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 8
- NHTMVDHEPJAVLT-UHFFFAOYSA-N Isooctane Chemical compound CC(C)CC(C)(C)C NHTMVDHEPJAVLT-UHFFFAOYSA-N 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 229910052802 copper Inorganic materials 0.000 description 8
- 239000011521 glass Substances 0.000 description 8
- 239000000380 hallucinogen Substances 0.000 description 8
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropyl acetate Chemical compound CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 8
- 230000005855 radiation Effects 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 208000007848 Alcoholism Diseases 0.000 description 7
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 7
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 7
- 229940011051 isopropyl acetate Drugs 0.000 description 7
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 7
- 230000036651 mood Effects 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- 208000020685 sleep-wake disease Diseases 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 229940124597 therapeutic agent Drugs 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 201000007930 alcohol dependence Diseases 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 239000012455 biphasic mixture Substances 0.000 description 6
- 229960003920 cocaine Drugs 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 201000000980 schizophrenia Diseases 0.000 description 6
- 238000000371 solid-state nuclear magnetic resonance spectroscopy Methods 0.000 description 6
- 241000218236 Cannabis Species 0.000 description 5
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 5
- 206010026749 Mania Diseases 0.000 description 5
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 5
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 5
- 201000001880 Sexual dysfunction Diseases 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 5
- 239000012267 brine Substances 0.000 description 5
- 229960001948 caffeine Drugs 0.000 description 5
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- 208000020016 psychiatric disease Diseases 0.000 description 5
- 231100000872 sexual dysfunction Toxicity 0.000 description 5
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- YHWMFDLNZGIJSD-UHFFFAOYSA-N 2h-1,4-oxazine Chemical compound C1OC=CN=C1 YHWMFDLNZGIJSD-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- 208000022497 Cocaine-Related disease Diseases 0.000 description 4
- 229920002785 Croscarmellose sodium Polymers 0.000 description 4
- 206010012289 Dementia Diseases 0.000 description 4
- 206010013654 Drug abuse Diseases 0.000 description 4
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 4
- 208000026251 Opioid-Related disease Diseases 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 4
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 229960001681 croscarmellose sodium Drugs 0.000 description 4
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 208000024714 major depressive disease Diseases 0.000 description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 4
- 239000008108 microcrystalline cellulose Substances 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 201000009032 substance abuse Diseases 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 3
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 3
- 208000029197 Amphetamine-Related disease Diseases 0.000 description 3
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 208000003863 Marijuana Abuse Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 208000006199 Parasomnias Diseases 0.000 description 3
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 206010013663 drug dependence Diseases 0.000 description 3
- 239000012065 filter cake Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 206010020765 hypersomnia Diseases 0.000 description 3
- 206010022437 insomnia Diseases 0.000 description 3
- 230000035987 intoxication Effects 0.000 description 3
- 231100000566 intoxication Toxicity 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 229960002715 nicotine Drugs 0.000 description 3
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 238000001757 thermogravimetry curve Methods 0.000 description 3
- 238000005292 vacuum distillation Methods 0.000 description 3
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 2
- 208000008811 Agoraphobia Diseases 0.000 description 2
- 206010001605 Alcohol poisoning Diseases 0.000 description 2
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 2
- 208000020925 Bipolar disease Diseases 0.000 description 2
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 2
- 208000017781 Cocaine intoxication Diseases 0.000 description 2
- 206010012239 Delusion Diseases 0.000 description 2
- 208000020401 Depressive disease Diseases 0.000 description 2
- 206010054089 Depressive symptom Diseases 0.000 description 2
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 2
- 206010016754 Flashback Diseases 0.000 description 2
- 208000004547 Hallucinations Diseases 0.000 description 2
- 101001125071 Homo sapiens Neuromedin-K receptor Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 2
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 102000002002 Neurokinin-1 Receptors Human genes 0.000 description 2
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 description 2
- 102100029409 Neuromedin-K receptor Human genes 0.000 description 2
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 2
- 206010034912 Phobia Diseases 0.000 description 2
- 206010041250 Social phobia Diseases 0.000 description 2
- 208000011963 Substance-induced psychotic disease Diseases 0.000 description 2
- 231100000393 Substance-induced psychotic disorder Toxicity 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 208000028505 alcohol-related disease Diseases 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 230000003109 amnesic effect Effects 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 201000001843 cannabis dependence Diseases 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000005388 cross polarization Methods 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 231100000868 delusion Toxicity 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000007888 film coating Substances 0.000 description 2
- 238000009501 film coating Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 229910000856 hastalloy Inorganic materials 0.000 description 2
- 229920001903 high density polyethylene Polymers 0.000 description 2
- 239000004700 high-density polyethylene Substances 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229960001375 lactose Drugs 0.000 description 2
- 229960001021 lactose monohydrate Drugs 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 208000019906 panic disease Diseases 0.000 description 2
- 239000000123 paper Substances 0.000 description 2
- 208000020861 perceptual disease Diseases 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 201000001716 specific phobia Diseases 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 2
- ILWRPSCZWQJDMK-UHFFFAOYSA-N triethylazanium;chloride Chemical compound Cl.CCN(CC)CC ILWRPSCZWQJDMK-UHFFFAOYSA-N 0.000 description 2
- CTSBUHPWELFRGB-SECBINFHSA-N (2r)-2-(benzylamino)-3-hydroxypropanoic acid Chemical compound OC[C@H](C(O)=O)NCC1=CC=CC=C1 CTSBUHPWELFRGB-SECBINFHSA-N 0.000 description 1
- LAHROJZLGLNLBT-SNVBAGLBSA-N (3r)-4-benzyl-5-oxomorpholine-3-carboxylic acid Chemical compound OC(=O)[C@H]1COCC(=O)N1CC1=CC=CC=C1 LAHROJZLGLNLBT-SNVBAGLBSA-N 0.000 description 1
- SFXMAWRMNYQCON-GJZGRUSLSA-N (7s,9as)-7-(phenylmethoxymethyl)-1,3,4,6,7,8,9,9a-octahydropyrazino[2,1-c][1,4]oxazine Chemical compound C([C@H]1NC[C@H]2COCCN2C1)OCC1=CC=CC=C1 SFXMAWRMNYQCON-GJZGRUSLSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 208000021465 Brief psychotic disease Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 description 1
- 206010012225 Delirium tremens Diseases 0.000 description 1
- 208000024254 Delusional disease Diseases 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 208000011688 Generalised anxiety disease Diseases 0.000 description 1
- 229910004373 HOAc Inorganic materials 0.000 description 1
- 238000010268 HPLC based assay Methods 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 208000016588 Idiopathic hypersomnia Diseases 0.000 description 1
- 208000001456 Jet Lag Syndrome Diseases 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- 235000013878 L-cysteine Nutrition 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 206010057852 Nicotine dependence Diseases 0.000 description 1
- 208000000224 Night Terrors Diseases 0.000 description 1
- 206010029412 Nightmare Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
- 206010033664 Panic attack Diseases 0.000 description 1
- 206010052794 Panic disorder with agoraphobia Diseases 0.000 description 1
- 206010033668 Panic disorder without agoraphobia Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 208000005793 Restless legs syndrome Diseases 0.000 description 1
- 208000020186 Schizophreniform disease Diseases 0.000 description 1
- 208000000810 Separation Anxiety Diseases 0.000 description 1
- 208000019568 Shared Paranoid disease Diseases 0.000 description 1
- 208000028810 Shared psychotic disease Diseases 0.000 description 1
- 206010041010 Sleep terror Diseases 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 206010041347 Somnambulism Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 231100000643 Substance intoxication Toxicity 0.000 description 1
- 208000011962 Substance-induced mood disease Diseases 0.000 description 1
- 231100000395 Substance-induced mood disorder Toxicity 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000025569 Tobacco Use disease Diseases 0.000 description 1
- 208000031674 Traumatic Acute Stress disease Diseases 0.000 description 1
- ZMTLLBSMRSGNSQ-YDALLXLXSA-N [(3s)-4-benzylmorpholin-3-yl]methanol;hydrochloride Chemical compound Cl.OC[C@H]1COCCN1CC1=CC=CC=C1 ZMTLLBSMRSGNSQ-YDALLXLXSA-N 0.000 description 1
- UCDFBOLUCCNTDQ-YFKPBYRVSA-N [(3s)-morpholin-3-yl]methanol Chemical compound OC[C@H]1COCCN1 UCDFBOLUCCNTDQ-YFKPBYRVSA-N 0.000 description 1
- WFLUDHYXVXRFLY-JEDNCBNOSA-N [(3s)-morpholin-3-yl]methanol;hydrochloride Chemical compound Cl.OC[C@H]1COCCN1 WFLUDHYXVXRFLY-JEDNCBNOSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000026345 acute stress disease Diseases 0.000 description 1
- 208000012826 adjustment disease Diseases 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 206010001584 alcohol abuse Diseases 0.000 description 1
- 208000025746 alcohol use disease Diseases 0.000 description 1
- 208000029650 alcohol withdrawal Diseases 0.000 description 1
- 208000006246 alcohol withdrawal delirium Diseases 0.000 description 1
- 239000003263 anabolic agent Substances 0.000 description 1
- 229940070021 anabolic steroids Drugs 0.000 description 1
- 239000000538 analytical sample Substances 0.000 description 1
- 229940005530 anxiolytics Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 150000008107 benzenesulfonic acids Chemical class 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 208000028683 bipolar I disease Diseases 0.000 description 1
- 208000022257 bipolar II disease Diseases 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- MCQRPQCQMGVWIQ-UHFFFAOYSA-N boron;methylsulfanylmethane Chemical compound [B].CSC MCQRPQCQMGVWIQ-UHFFFAOYSA-N 0.000 description 1
- 201000009322 cannabis abuse Diseases 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 206010007776 catatonia Diseases 0.000 description 1
- 239000011093 chipboard Substances 0.000 description 1
- 201000001272 cocaine abuse Diseases 0.000 description 1
- 201000006145 cocaine dependence Diseases 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000019788 craving Nutrition 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 208000026725 cyclothymic disease Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- JVSWJIKNEAIKJW-UHFFFAOYSA-N dimethyl-hexane Natural products CCCCCC(C)C JVSWJIKNEAIKJW-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 208000024732 dysthymic disease Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 208000029364 generalized anxiety disease Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000003400 hallucinatory effect Effects 0.000 description 1
- 201000002270 hallucinogen abuse Diseases 0.000 description 1
- 201000006138 hallucinogen dependence Diseases 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 201000003631 narcolepsy Diseases 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 239000001272 nitrous oxide Substances 0.000 description 1
- 238000013421 nuclear magnetic resonance imaging Methods 0.000 description 1
- 201000005040 opiate dependence Diseases 0.000 description 1
- 201000000988 opioid abuse Diseases 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 1
- 208000002851 paranoid schizophrenia Diseases 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 208000028173 post-traumatic stress disease Diseases 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 208000022610 schizoaffective disease Diseases 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 208000025874 separation anxiety disease Diseases 0.000 description 1
- 208000012201 sexual and gender identity disease Diseases 0.000 description 1
- 208000015891 sexual disease Diseases 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 208000022925 sleep disturbance Diseases 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 231100000736 substance abuse Toxicity 0.000 description 1
- 201000006152 substance dependence Diseases 0.000 description 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- FQFILJKFZCVHNH-UHFFFAOYSA-N tert-butyl n-[3-[(5-bromo-2-chloropyrimidin-4-yl)amino]propyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCCNC1=NC(Cl)=NC=C1Br FQFILJKFZCVHNH-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002076 thermal analysis method Methods 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- BWHDROKFUHTORW-UHFFFAOYSA-N tri-tert-butylphosphine Substances CC(C)(C)P(C(C)(C)C)C(C)(C)C BWHDROKFUHTORW-UHFFFAOYSA-N 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23743509P | 2009-08-27 | 2009-08-27 | |
| US237435P | 2009-08-27 | ||
| PCT/EP2010/062420 WO2011023733A1 (en) | 2009-08-27 | 2010-08-25 | Anhydrate forms of a pyridine derivative |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2440938T3 true ES2440938T3 (es) | 2014-01-31 |
Family
ID=42790943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES10747619.4T Active ES2440938T3 (es) | 2009-08-27 | 2010-08-25 | Formas anhidrato de un derivado de piridina |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US8796269B2 (member.php) |
| EP (1) | EP2470545B1 (member.php) |
| JP (3) | JP2013503134A (member.php) |
| KR (1) | KR20120056258A (member.php) |
| CN (1) | CN102639536B (member.php) |
| AU (1) | AU2010288502B2 (member.php) |
| BR (1) | BR112012003435A2 (member.php) |
| CA (1) | CA2772168C (member.php) |
| DK (1) | DK2470545T3 (member.php) |
| EA (1) | EA021411B1 (member.php) |
| ES (1) | ES2440938T3 (member.php) |
| IL (1) | IL217922A (member.php) |
| IN (1) | IN2012DN01292A (member.php) |
| MX (1) | MX2012002369A (member.php) |
| PL (1) | PL2470545T3 (member.php) |
| SG (1) | SG178231A1 (member.php) |
| WO (1) | WO2011023733A1 (member.php) |
| ZA (1) | ZA201200812B (member.php) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA021411B1 (ru) * | 2009-08-27 | 2015-06-30 | Нерр Терапьютикс Лимитед | Безводная форма производного пиридина |
| US10314835B2 (en) | 2014-06-25 | 2019-06-11 | Emory University | Methods of managing conditioned fear with neurokinin receptor antagonists |
| PL3297631T3 (pl) * | 2015-05-18 | 2020-03-31 | Nerre Therapeutics Limited | Antagoniści receptora NK-1/NK-3 do leczenia uderzeń gorąca |
| BR112019012300A2 (pt) * | 2016-12-15 | 2019-11-12 | Glaxosmithkline Intellectual Property Development Limited | ativadores nrf2 |
| UA128159C2 (uk) | 2018-03-14 | 2024-04-24 | Канді Терап'Ютікс Лімітед | Фармацевтичний препарат для капсули з м'якого желатину, який містить подвійний антагоніст рецептора nk-1/nk-3 |
| WO2021030335A1 (en) * | 2019-08-12 | 2021-02-18 | Millendo Therapeutics, Inc. | A stereoisomerically pure nk-3 receptor antagonist and crystalline forms thereof |
| JOP20220111A1 (ar) | 2019-11-15 | 2023-01-30 | Kandy Therapeutics Ltd | عملية كيميائية جديدة لتشكيل 6-كلورو-4- (4-فلورو-2-مثيل فنيل) بيريدين-3-أمين بصفته مركباً وسيطاً رئيسياً لـ nt-814 |
| EP4431512A1 (en) | 2023-03-16 | 2024-09-18 | Bayer Consumer Care AG | Novel dual nk-1/nk-3 receptor antagonists |
| WO2025242585A1 (en) | 2024-05-24 | 2025-11-27 | Bayer Consumer Care Ag | Crystalline forms of salts of elinzanetant and compositions containing salts of elinzanetant |
| WO2025242583A1 (en) | 2024-05-24 | 2025-11-27 | Bayer Consumer Care Ag | Novel formulation comprising elinzanetant in a solid dispersion |
| WO2025242584A1 (en) | 2024-05-24 | 2025-11-27 | Bayer Consumer Care Ag | A stable soft gelatin capsule formulation for elinzanetant |
| WO2025261856A1 (en) * | 2024-06-18 | 2025-12-26 | Bayer Consumer Care Ag | Improved process for producing an elinzanetant precursor |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2226622T3 (es) * | 1999-02-24 | 2005-04-01 | F. Hoffmann-La Roche Ag | Derivados de 4-fenil piridina y su empleo como antagonistas del receptor nk-1. |
| GB0203022D0 (en) * | 2002-02-08 | 2002-03-27 | Glaxo Group Ltd | Chemical compounds |
| KR100700421B1 (ko) * | 2003-01-31 | 2007-03-28 | 에프. 호프만-라 로슈 아게 | 2-(3,5-비스-트라이플루오로메틸-페닐)-Ｎ-[6-(1,1-다이옥소-1λ6-티오모폴린-4-일)-4-(4-플루오로-2-메틸-페닐)-피리딘-3-일]-Ｎ-메틸-아이소부티르아미드의 새로운 결정변형체 |
| ES2291891T3 (es) * | 2003-07-03 | 2008-03-01 | F. Hoffmann-La Roche Ag | Antagonistas duales de nk1/nk3 para tratamiento de esquizofrenia. |
| MY145713A (en) * | 2005-09-09 | 2012-03-30 | Smithkline Beecham Corp | Hexahydropyrazino [2,1-c][1,4]oxazin-8(1h)-yl pyridine derivatives and their use in the treatment of psychotic disorders |
| WO2009087667A2 (en) * | 2007-12-11 | 2009-07-16 | Cipla Ltd. | A new method for preparation of zopiclone and its polymorphs |
| GB0814340D0 (en) * | 2008-08-05 | 2008-09-10 | Smithkline Beecham Corp | Anhydrous crystol form fo a pyridine derivative |
| EA021411B1 (ru) * | 2009-08-27 | 2015-06-30 | Нерр Терапьютикс Лимитед | Безводная форма производного пиридина |
| JP6342662B2 (ja) * | 2014-01-29 | 2018-06-13 | 京セラ株式会社 | ドリルおよびそれを用いた切削加工物の製造方法 |
-
2010
- 2010-08-25 EA EA201270302A patent/EA021411B1/ru not_active IP Right Cessation
- 2010-08-25 CN CN201080037918.3A patent/CN102639536B/zh active Active
- 2010-08-25 BR BR112012003435A patent/BR112012003435A2/pt not_active Application Discontinuation
- 2010-08-25 MX MX2012002369A patent/MX2012002369A/es active IP Right Grant
- 2010-08-25 PL PL10747619T patent/PL2470545T3/pl unknown
- 2010-08-25 AU AU2010288502A patent/AU2010288502B2/en active Active
- 2010-08-25 EP EP10747619.4A patent/EP2470545B1/en active Active
- 2010-08-25 ES ES10747619.4T patent/ES2440938T3/es active Active
- 2010-08-25 JP JP2012526048A patent/JP2013503134A/ja active Pending
- 2010-08-25 IN IN1292DEN2012 patent/IN2012DN01292A/en unknown
- 2010-08-25 DK DK10747619.4T patent/DK2470545T3/da active
- 2010-08-25 KR KR1020127004865A patent/KR20120056258A/ko not_active Ceased
- 2010-08-25 SG SG2012007464A patent/SG178231A1/en unknown
- 2010-08-25 WO PCT/EP2010/062420 patent/WO2011023733A1/en not_active Ceased
- 2010-08-25 CA CA2772168A patent/CA2772168C/en active Active
- 2010-08-25 US US13/389,525 patent/US8796269B2/en active Active
-
2012
- 2012-02-02 ZA ZA2012/00812A patent/ZA201200812B/en unknown
- 2012-02-02 IL IL217922A patent/IL217922A/en active IP Right Grant
-
2015
- 2015-07-13 JP JP2015139845A patent/JP6404186B2/ja active Active
-
2017
- 2017-06-09 JP JP2017114602A patent/JP2017193564A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL217922A (en) | 2016-06-30 |
| CN102639536B (zh) | 2015-03-18 |
| ZA201200812B (en) | 2013-03-27 |
| AU2010288502B2 (en) | 2013-12-12 |
| MX2012002369A (es) | 2012-03-29 |
| CN102639536A (zh) | 2012-08-15 |
| JP2013503134A (ja) | 2013-01-31 |
| EA021411B1 (ru) | 2015-06-30 |
| BR112012003435A2 (pt) | 2016-02-23 |
| US20120157450A1 (en) | 2012-06-21 |
| JP6404186B2 (ja) | 2018-10-10 |
| EP2470545B1 (en) | 2013-10-09 |
| WO2011023733A1 (en) | 2011-03-03 |
| IL217922A0 (en) | 2012-03-29 |
| DK2470545T3 (da) | 2014-01-13 |
| JP2016000739A (ja) | 2016-01-07 |
| PL2470545T3 (pl) | 2014-03-31 |
| IN2012DN01292A (member.php) | 2015-06-05 |
| US8796269B2 (en) | 2014-08-05 |
| CA2772168A1 (en) | 2011-03-03 |
| AU2010288502A1 (en) | 2012-02-23 |
| JP2017193564A (ja) | 2017-10-26 |
| CA2772168C (en) | 2019-01-08 |
| KR20120056258A (ko) | 2012-06-01 |
| SG178231A1 (en) | 2012-03-29 |
| EP2470545A1 (en) | 2012-07-04 |
| EA201270302A1 (ru) | 2012-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2440938T3 (es) | Formas anhidrato de un derivado de piridina | |
| US20220153737A1 (en) | Solid forms of a compound modulating kinases | |
| AU2020378407B2 (en) | Heterocyclic RIP1 inhibitory compounds | |
| ES2618007T3 (es) | Nuevos compuestos de pirrolopirimidina como inhibidores de proteína cinasas | |
| RU2434851C1 (ru) | Циклические n, n'-диарилтиомочевины или n, n'-диарилмочевины - антагонисты андрогенных рецепторов, противораковое средство, способ получения и применения | |
| CN101868465B (zh) | 包含N-(5-叔丁基-异噁唑-3-基)-N’-{4-[7-(2-吗啉-4-基-乙氧基)咪唑并[2，1-b][1，3]苯并噻唑-2-基]苯基}脲的固体形式、其组合物及其应用 | |
| AU2018237047A2 (en) | Crystalline forms of 4-(1-(1,1-di(pyridin-2-yl)ethyl)-6-(3,5-dimethylisoxazol-4-yl)-1H- pyrrolo[3,2-b]pyridin-3-yl)benzoic acid that inhibits bromodomain | |
| EP2958911B1 (en) | Quinazolines as kinase inhibitors | |
| KR20190031518A (ko) | 치환된 디아자헤테로비시클릭 화합물 및 그의 용도 | |
| BR112014023460B1 (pt) | Composto, formulação farmacêutica, uso de um composto | |
| EA028175B1 (ru) | Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания | |
| RS57144B1 (sr) | Prolekovi kvinazolin amina kao inhibitori kinaze | |
| JP2021512942A (ja) | トリアゾール、イミダゾールおよびピロール縮合ピペラジン誘導体、およびｍＧｌｕ５受容体のモジュレータとしてのそれらの使用 | |
| US9085539B2 (en) | Cyclic N,N′-diarylthiourea—androgen receptor antagonist, anti breast cancer composition and use thereof | |
| EP4313972B1 (en) | Indoline derivatives as ddrs inhibitors | |
| HK1248223A1 (en) | Solid forms of a compound modulating kinases | |
| HK1248223B (en) | Solid forms of a compound modulating kinases | |
| HK1212223B (en) | Prodrugs of amino quinazoline kinase inhibitor |